Headed by Gordon Mills and Rehan Akbanie, the MD Anderson GCC will use reverse phase protein arrays to investigate tumor tissue from a variety of NCI projects.
The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.
The funds will support a multi-center clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.
Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.
The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.
In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.